Last reviewed · How we verify
Glucosamine sulfate + chondroitin sulfate - CONDROFLEX
Glucosamine sulfate and chondroitin sulfate work together to provide substrate for cartilage synthesis and reduce cartilage degradation in osteoarthritis.
Glucosamine sulfate and chondroitin sulfate work together to provide substrate for cartilage synthesis and reduce cartilage degradation in osteoarthritis. Used for Osteoarthritis of the knee, Osteoarthritis of other joints.
At a glance
| Generic name | Glucosamine sulfate + chondroitin sulfate - CONDROFLEX |
|---|---|
| Also known as | Condroflex ® |
| Sponsor | Mantecorp Industria Quimica e Farmaceutica Ltd. |
| Drug class | Nutraceutical/Chondroprotective agent |
| Modality | Small molecule |
| Therapeutic area | Rheumatology/Orthopedics |
| Phase | Phase 3 |
Mechanism of action
Glucosamine sulfate serves as a precursor for glycosaminoglycan synthesis, supporting cartilage matrix formation and repair. Chondroitin sulfate inhibits cartilage-degrading enzymes and may reduce inflammatory mediators. Together, these agents aim to slow cartilage loss and potentially promote cartilage regeneration in degenerative joint disease.
Approved indications
- Osteoarthritis of the knee
- Osteoarthritis of other joints
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Mild allergic reactions
Key clinical trials
- A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study (PHASE3)
- Clinical Study of Non-inferiority With Participants Diagnosed With Primary Knee OA (GLACIAL) (PHASE3)
- Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis (PHASE3)
- Study With Chondroitin Sulfate and Glucosamine Sulfate (in Dosage Capsule and Sachet) in Treating Osteoarthritis (PHASE3)
- Non-inferiority Study of the Glucosamine Sulfate + Chondroitin Sulfate Association Capsule in Comparison to the CONDROFLEX® Product in Osteoarthrosis of the Knee (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: